.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,168,778

« Back to Dashboard

Details for Patent: 6,168,778

Title: Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
Abstract:This invention discloses a method for preparing a complex comprised of a VEGF Nucleic Acid Ligand and a Lipophilic Compound by identifying a VEGF Nucleic Acid Ligand by SELEX methodology and associating the VEGF Nucleic Acid Ligand with a Lipophilic Compound. The invention further discloses Complexes comprising one or more VEGF Nucleic Acid Ligands in association with a Lipophilic Compound. The invention further includes a Lipid construct comprising a VEGF Nucleic Acid Ligand or Complex and methods for making the same.
Inventor(s): Janjic; Nebojsa (Boulder, CO), Gold; Larry (Boulder, CO), Schmidt; Paul (Niwot, CO), Vargeese; Chandra (Thornton, CO)
Assignee: NeXstar Pharmaceuticals, Inc. (Boulder, CO)
Filing Date:Jun 06, 1997
Application Number:08/870,930
Claims:1. A Complex comprised of a VEGF Nucleic Acid Ligand comprising 2'F-modified nucleotides and a Lipophilic Compound.

2. The Complex of claim 1 wherein said Lipophilic Compound is a glycerol lipid.

3. The Complex of claim 2 wherein said Lipophilic compound is a glycerol lipid having the structure ##STR14##

where R.sup.1, R.sup.2, and R.sup.3 are independently selected from the group consisting of CH.sub.3 (CH.sub.2).sub.n --O(PO.sub.3)--CH.sub.2 --; and CH.sub.3 (CH.sub.2).sub.n --CONH.sub.2 --CH.sub.2 --, CH.sub.3 (CH.sub.2).sub.n O--, CH.sub.3 (CH.sub.2).sub.n OCH.sub.2 --, CH.sub.3 (CH.sub.2).sub.n (CO)OCH.sub.2 --, CH.sub.3 (CH.sub.2).sub.n (CO)O-- and X--, wherein at least one must be X--, and X is independently selected from the group consisting of (PO.sub.4), and O, and wherein n=0-30, preferably 10-20.

4. The Complex of claim 3 wherein said glycerol lipid is a phospholipid wherein one of R.sup.1, R.sup.2, or R.sup.3 is CH.sub.3 (CH.sub.2).sub.n --O(PO.sub.3)--CH.sub.2 --.

5. The Complex claim 4 wherein R.sup.1 is CH.sub.3 (CH.sub.2).sub.n --O(PO.sub.3)--CH.sub.2 --, R.sup.2 is CH.sub.3 (CH.sub.2).sub.n --O(PO.sub.3)--CH.sub.2 --, and R.sup.3 is X--, and wherein n=17.

6. The Complex of claim 5 wherein X is PO.sub.4.

7. The Complex of claim 3 wherein said glycerol lipid is a glycerol amide lipid wherein one of R.sup.1, R.sup.2 or R.sup.3 is CH.sub.3 (CH.sub.2).sub.n --CONH.sub.2 --CH.sub.2 --.

8. The Complex of claim 7 wherein R.sup.1 is CH.sub.3 (CH.sub.2).sub.n --CONH.sub.2 --CH.sub.2 --, R.sup.2 is CH.sub.3 (CH.sub.2).sub.n --CONH.sub.2 --CH.sub.2 --, and R.sup.3 is X--, and wherein n=16.

9. The Complex of claim 8 wherein X is PO.sub.4.

10. The Complex of claim 8 wherein X is O.

11. A Lipid Construct comprising the Complex of claim 1.

12. A Lipid Construct comprising the Complex of claim 3.

13. A Lipid Construct comprising the Complex of claim 4.

14. A Lipid Construct comprising the Complex of claim 5.

15. A Lipid Construct comprising the Complex of claim 6.

16. The Lipid Construct of claim 15 wherein said Complex is ##STR15##

Ligand Component=fCmGmGrArAfUfCmAmGfUmGmAmAfUmGfCfUfUmAfUmAfCmAfUfCfCmG-3'3'-dT (VEGF ligand) (SEQ ID NO:5).

17. A Lipid Construct comprising the Complex of claim 7.

18. A Lipid Construct comprising the Complex of claim 8.

19. A Lipid Construct comprising the Complex of claim 9.

20. The Lipid Construct of claim 19 wherein said Complex is ##STR16##

Ligand Component=fCmGmGrArAfUfCmAmGfUmGmAmAfUmGfCfUfUmAfUmAfCmAfUfCfCmG-3'3'-dT (VEGF ligand) (SEQ ID NO:6).

21. A Lipid Construct comprising the Complex of claim 10.

22. The Lipid Construct of claim 21 wherein said Complex is ##STR17##

Ligand Component=fCmGmGrArAfUfCmAmGfUmGmAmAfUmGfCfUfUmAfUmAfCmAfUfCfCmG-3'3'-dT (VEGF ligand) (SEQ ID NO:7).

23. A method for the preparation of a Complex comprised of a VEGF Nucleic Acid Ligand comprising 2'-F-modified nucleotides and a Non-Immunogenic, High Molecular Weight Com-pound of Lipophilic Compound, said method comprising:

a) identifying a VEGF Nucleic Acid Ligand from a Candidate Mixture of Nucleic Acids by the method comprising:

(i) contacting the Candidate Mixture with VEGF, wherein Nucleic Acids having increased affinity to VEGF relative to the Candidate Mixture may be partitioned from the remainder of the Candidate Mixture;

(ii) partitioning the increased affinity VEGF Nucleic Acids from the remainder of the Candidate Mixture;

(iii) amplifying the increased affinity VEGF Nucleic Acids to yield a ligand-enriched mixture of Nucleic Acids; and

b) forming a covalent bond between said identified VEGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound of Lipophilic Compound.

24. The method of claim 23 wherein said Complex is further associated with a Lipid Construct.

25. The method of claim 24 wherein said Lipid Construct is a Liposome.

26. The method of claim 25 wherein said Complex is comprised of a Nucleic Acid Ligand and a Lipophilic Compound and wherein said Complex is associated with the bilayer of said Liposomes by the method comprising the steps of:

a) forming a liposome; and

b) mixing said Complex comprised of a Nucleic Acid Ligand and a Lipophilic Compound with the Liposomes of step a) whereby the Nucleic Acid Ligand Component of said Complex becomes associated with the bilayer of the Liposome and projects from the exterior of the Lipid bilayer.

27. The method of claim 23 wherein said Non-Immunogenic, High Molecular Weight Compound is Polyalkylene Glycol.

28. The method of claim 27 wherein said Polyalkylene Glycol is polyethylene glycol.

29. The method of claim 28 wherein said polyethylene glycol has a molecular weight of about between 10-80 K.

30. The method of claim 29 wherein said polyethylene glycol has a molecular weight of about 20-45 K.

31. The method of claim 30 wherein said Complex has the structure ##STR18##

Ligand Component=fCmGmGrArAfUfCmAmGfUmGmAmAfUmGfCfUfUmAfUmAfCmAfUfCfCmG-3'3'-dT (VEGF ligand) (SEQ ID NO: 8).

32. The method of claim 30 wherein said Complex has the structure ##STR19##

Ligand Component=fCmGmGrArAfUfCmAmGfUmGmAmAfUmGfCfUfUmAfUmAfCmAfUfCfCmG-3'3'-dT (VEGF ligand) (SEQ ID NO: 9).

33. The method of claim 24 wherein said Complex is ##STR20##

Ligand Component=fCmGmGrArAfUfCmAmGfUmGmAmAfUmGfCfUfUmAfUmAfCmAfUfCfCmG-3'3'-dT (VEGF ligand) (SEQ ID NO: 5).

34. The method of claim 24 wherein said Complex is ##STR21##

Ligand Component=fCmGmGrArAfUfCmAmGfUmGmAmAfUmGfCfUfUmAfUmAfCmAfUfCfCmG-3'3'-dT (VEGF ligand) (SEQ ID NO:6).

35. The method of claim 24 wherein said Complex is ##STR22##

Ligand Component=fCmGmGrArAfUfCmAmGfUmGmAmAfUmGfCfUfUmAfUmAfCmAfUfCfCmG-3'3'-dT (VEGF ligand) (SEQ ID NO: 7).
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc